rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    DESK
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Simplify Health Care ETF vs. VanEck Biotech ETF: One Critical Difference Could Shape Future Returns | The Motley Fool

      These two healthcare ETFs take fundamentally different approaches to investing, with meaningful differences in diversification, management strategy, and long-term return potential.

      Nov 12The Motley FoolBBHDESKPINK
      This ETF Is Down 24% From Its Peak. Here's Why I'm Buying More. | The Motley Fool

      The VanEck Semiconductor ETF's slump is nasty, but could prove to be a compelling buying opportunity.

      Nov 5The Motley FoolSMHDESK
      1 Unstoppable ETF I'm Buying Hand Over Fist During the Next Bear Market

      Motley Fool Press Release.

      Nov 1The Globe and MailDESK
      Can GLP-1s Fatten Your Portfolio? We Examine the VanEck Pharmaceutical ETF vs State Street SPDR Pharmaceuticals ETF | The Motley Fool

      VanEck's concentrated 26-stock portfolio delivered stronger five-year returns and lower volatility, while State Street's 62-holding fund offers broader diversification and lower fees.

      Oct 30The Motley FoolPPHSTTDESK
      A Simple Rule for the Semiconductor ETF: Buy After a 15% Drop. Here's How It Has Done Since 2012. | The Motley Fool

      The rule fired again in July. How much should investors trust a 7-for-8 record?

      Oct 28The Motley FoolSMHDESK
      Which Biotech ETF Is the Better Buy: VanEck’s BBH or Invesco’s Factor-Driven PBE? | The Motley Fool

      BBH offers lower costs and concentrated large-cap exposure, while PBE delivers higher dividend income and slightly better five-year returns through a multifactor strategy.

      Oct 27The Motley FoolBBHIVZDESK
      Which Pharmaceutical ETF Is the Better Buy: iShares’ Domestic IHE or VanEck’s Global PPH? | The Motley Fool

      IHE has outperformed recently by concentrating in U.S. drugmakers. PPH offers global reach and a higher dividend for investors willing to trade some of that momentum for income.

      Oct 26The Motley FoolPPHDESKIHE
      VanEck Biotech vs. Invesco Healthcare: Which ETF Offers More Potential for Long-Term Growth? | The Motley Fool

      These two healthcare ETFs offer investors exposure to some of medicine's biggest names, but their different approaches to investing could lead to very different results.

      Oct 25The Motley FoolBBHIVZDESKRSPH
      Better Clean Energy ETF: VanEck's Nuclear-Focused NLR vs. the iShares ICLN Targeting Renewables | The Motley Fool

      VanEck's uranium fund yields 3.1% but lost 28% last year, while iShares' renewable portfolio gained 8.3% with lower costs.

      Oct 15The Motley FoolICLNDESK
      Which Healthcare ETF Is the Better Buy: Simplify’s Active PINK or VanEck’s Pharma-Focused PPH? | The Motley Fool

      VanEck offers lower costs and higher dividends with a concentrated pharma focus, while Simplify provides broader healthcare exposure and donates profits to breast cancer research.

      Oct 11The Motley FoolPPHDESKPINK
      Which Precious Metals ETF Is the Better Buy: abrdn’s Silver SIVR or VanEck’s Gold Miners GDX? | The Motley Fool

      Physical silver offers lower costs and no dividend, while gold miners provide equity diversification and income. Which metals strategy fits your portfolio?

      Oct 11The Motley FoolDESKGDXSIVRSILVER
      Better Biotechnology ETF: First Trust FBT vs. VanEck BBH | The Motley Fool

      VanEck's lower 0.35% expense ratio appeals to cost-conscious investors, while First Trust's $2.9 billion in assets and equal-weighted approach offer broader diversification across 30 biotech holdings.

      Oct 10The Motley FoolBBHDESKFBT
      Better Healthcare ETF: VanEck's Biotech-Focused BBH vs. State Street's XPH Targeting Pharma | The Motley Fool

      BBH concentrates on 25 large-cap biotech leaders, while XPH diversifies across 62 pharmaceutical holdings. Both charge 0.35% annually, but their five-year returns diverged significantly.

      Oct 10The Motley FoolBBHDESKXPH
      Better Energy ETF: VanEck's Nuclear-Focused NLR vs. State Street's XOP Oil and Gas Fund | The Motley Fool

      State Street's oil and gas fund surged 43.6% in one year while the nuclear fund declined 24.8%, yet both delivered similar five-year growth.

      Oct 9The Motley FoolSTTDESKXOP
      Better Pharmaceuticals ETF: VanEck's PPH vs. Invesco PJP | The Motley Fool

      VanEck offers lower costs and double the dividend yield, while Invesco delivered stronger 1-year returns with more balanced holdings.

      Oct 3The Motley FoolPPHIVZDESK
      If I Could Only Add 1 ETF to My Portfolio This Year, Here's Exactly What I'd Buy | The Motley Fool

      This semiconductor ETF continues to look ripe for more gains.

      Sep 25The Motley FoolDESK
      This Unstoppable ETF Is Down 12% From Its High -- and History Says Now Is a Smart Time to Invest

      Detailed price information for Broadcom Ltd (AVGO-Q) from The Globe and Mail including charting and trades.

      Sep 23The Globe and MailDESK
      VanEck Pharmaceutical ETF vs VanEck Biotech ETF: Which Fund Is Better for Drug Innovation Profits? | The Motley Fool

      PPH offers higher income and lower volatility, while BBH delivers stronger growth but with deeper drawdowns.

      Sep 15The Motley FoolBBHPPHDESK
      Better Short-Term Bond ETF: Schwab's Treasury-Focused SCHO or VanEck's SMB Targeting Municipal Bonds | The Motley Fool

      SCHO charges half VanEck's fee while delivering a 1.09 percentage point yield advantage and stronger five-year returns.

      Sep 8The Motley FoolDESK
      Which Healthcare ETF Offers the Better Growth Outlook: VanEck Biotech or Invesco Pharmaceuticals? | The Motley Fool

      VanEck focuses on a clutch of biotech leaders with lower fees; Invesco tracks a select group of pharma companies with higher dividend yield and stronger five-year returns.

      Aug 28The Motley FoolBBHIVZDESK
      Gold Is Still Historically High. Is VanEck Gold Miners ETF or Sprott Gold Miners ETF the Better Way to Play Bullion's Strength? | The Motley Fool

      Sprott offers lower fees and higher dividend yield, while VanEck commands $31 billion in assets with broader global exposure to mining companies.

      Aug 25The Motley FoolGOLDSIIDESKGDXSGDM
      Which Biotech ETF Is a Better Buy: Concentrated Bet or Broad Basket? | The Motley Fool

      VanEck's concentrated 25-stock approach offers higher individual company exposure, while Invesco's broader 251-position portfolio delivered 47.4% returns over the past year.

      Aug 22The Motley FoolBBHIBBQDESK

      This is the newest page. Registered accounts read further back.